- What is rosacea and how to recognize it? - February 3, 2026
- Impetigo: what it is and when to seek medical advice - February 2, 2026
- Bactrim in Spain: what is its equivalent in pharmacies? - February 1, 2026
The pharmacy price of Mounjaro in Spain ranges from โฌ207.91 to โฌ446.07 depending on the dose. The 5 mg KwikPen, with 4 doses, costs โฌ271.35, and the 10 mg pen costs โฌ358.71. For prices of other doses, see the complete table below.
What is the Mounjaro pharmacy price by dose in Spain?
The retail price including VAT that you see published is per presentation, that is, per KwikPen dispensed with a prescription. The price corresponds to the complete pen, not a single injection.
| Mounjaro's presentation | RRP including VAT |
|---|---|
| 2.5 mg | โฌ207.91 |
| 5 mg | โฌ271.35 |
| 7.5 mg | โฌ358.71 |
| 10 mg | โฌ358.71 |
| 12.5 mg | โฌ446.07 |
| 15 mg | โฌ446.07 |
How does that price become a monthly cost?
The conversion is fairly straightforward because Mounjaro is administered once a week, and each KwikPen multidose pen is designed for four doses, so one pen typically lasts for about four weeks. If someone wants to estimate the cost per injection, they usually divide the price of the pen by four.
What is the usual dosage and why might the price change?
The standard regimen usually starts with 2.5 mg once a week for four weeks, then increases to 5 mg once a week. If necessary, your doctor may increase the dose in 2.5 mg increments after at least four weeks at the previous dose. This means your out-of-pocket expenses may change over time if your dose changes.
Is a prescription required and is it covered by Spainโs public health system?
A prescription is required because it is a prescription medication. Currently, BIFIMED lists it as not publicly funded, so it is usually paid for privately at a pharmacy.
Is Mounjaro approved by the AEMPS?
Mounjaro received centralized marketing authorization in the European Union in September 2022. Since July 1, 2024, it has been marketed in Spanish pharmacies with a prescription for type 2 diabetes and weight or obesity control.
How is it different from Ozempic?
Unlike Ozempic (GLP-1 agonist), Mounjaro acts on both GLP-1 and GIP receptors, which enhances satiety, improves glycemic control and promotes greater weight loss.
In clinical trials, patients treated with tirzepatide (such as Mounjaro) achieved weight losses of around 20% of body weight, exceeding typical semaglutide results.
Important: This text is for informational purposes only and does not replace medical advice. Always consult the official package leaflet and follow the prescription and instructions of your doctor or pharmacist.
